Novo Nordisk’s Oral Semaglutide Demonstrates Potential to be the First Oral GLP-1 RA Therapy for Children and Adolescents with Type 2 Diabetes
Summary
Bagsv rd, Denmark, 23 April 2026 Novo Nordisk today announced positive topline results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type
Description
Bagsv rd, Denmark, 23 April 2026 Novo Nordisk today announced positive topline results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source